Novo Nordisk targets turn-of-decade launch for triple-G obesity shot

Novo Nordisk targets a ~2030 launch for UBT251, a triple-G obesity drug showing up to 19.7% weight loss in a China Phase 2.

Raccontata daendpoints.news